Opendata, web and dolomites

easierNGS

CERTIFIED PACKS FOR EASIER NEXT-GENERATION SEQUENCING CLINICAL DIAGNOSTICS

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "easierNGS" data sheet

The following table provides information about the project.

Coordinator
STAB VIDA INVESTIGACAO E SERVICOS EM CIENCIAS BIOLOGICAS LDA 

Organization address
address: RUA DOS INVENTORES S/N EDIFICIO MADAN PARQUE SALAS 2.18 E 2.19
city: CAPARICA
postcode: 2825 182
website: www.stabvida.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2014
 Duration (year-month-day) from 2014-10-01   to  2015-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STAB VIDA INVESTIGACAO E SERVICOS EM CIENCIAS BIOLOGICAS LDA PT (CAPARICA) coordinator 50˙000.00

Map

 Project objective

Next-generation sequencing (NGS) has revolutionized genomic research by drastically decreasing the cost of sequencing and increasing the throughput of generated data, but still has not been able to reach its implementation in clinical diagnostic laboratories where there is a huge potential market application for it. The current market gold-standard in clinical diagnostic (i.e. Sanger-based sequencing) is outdated, much less efficient and more expensive than NGS, but no current market solutions have yet been able to properly address the complexity involved in transferring and validating gold-standard procedures to NGS platforms in clinical environment. In fact, current competing solutions are disruptive, complex, non-efficient and non-validated to address the challenges of transferring NGS to clinics. The easierNGS business concept aims to create and offer an innovative package of services and products which combined will allow a fast, cost-effective, streamlined and certified full sample-to-result solution to clinical laboratories that wish to seize the tremendous benefits of the new NGS era. Towards this objective, a feasibility assessment of the easierNGS business concept will be conducted to better determine its technical, economic and legal viability, as well as plan its most appropriate operational and scheduling strategy. Three case studies (i.e. NGS panels for pharmacogenomics, neonatal screening and infertility risk factors) will be used to generate a proof-of-concept of the easierNGS and help define the technical aspects and guidelines for future easierNGS packages and support a conscientious “Go/No go” decision towards a real market assessment.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EASIERNGS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EASIERNGS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

N-IF (2017)

The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Read More